Stock SYRE SPYRE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
33.56 USD +3.36% Intraday chart for Spyre Therapeutics, Inc. +3.55% +55.95%
Apr. 19 Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
Apr. 19 Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Steady Pre-Bell Friday
MT
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aeglea BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Aeglea BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (AGLE) AEGLEA BIOTHERAPEUTICS Posts Q2 Revenue $688,000
MT
Aeglea BioTherapeutics Sells Rights to Investigational Metabolic Disease Treatment to Immedica Pharma; Shares Rise Pre-Bell
MT
Aeglea BioTherapeutics, Inc. Enters into Agreement with Immedica Pharma AB
CI
Immedica Pharma acquired global rights to pegzilarginase from Aeglea BioTherapeutics, Inc. for approximately $120 million.
CI
Aeglea BioTherapeutics Acquires Spyre Therapeutics; Shares Surge Pre-Bell
MT
Aeglea BioTherapeutics, Inc. acquired Spyre Therapeutics, Inc.
CI
Earnings Flash (AGLE) AEGLEA BIOTHERAPEUTICS Posts Q1 Revenue $198,000
MT
Aeglea BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
North American Morning Briefing : Caution -2-
DJ
Aeglea BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Anticipation Ahead of Powell's Speech Supports Modest Rise in Exchange Traded Funds Premarket Wednesday
MT
Earnings Flash (AGLE) AEGLEA BIOTHERAPEUTICS Posts Q3 Revenue $174,000
MT
Earnings Flash (AGLE) AEGLEA BIOTHERAPEUTICS Posts Q3 Loss $-0.19
MT
Aeglea BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Aeglea BioTherapeutics Says FDA Places Partial Clinical Hold on Enrollment of Patients Under 18 in Pegtarviliase Trial
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SYRE Stock
  4. News Spyre Therapeutics, Inc.
  5. Highlights